Filing Details
- Accession Number:
- 0001209191-21-059698
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2021-10-05 19:21:54
- Reporting Period:
- 2021-08-23
- Accepted Time:
- 2021-10-05 19:21:54
- SEC Url:
- Form 4 Filing
Issuer
| Cik | Name | Symbol | Sector (SIC) | IRS No |
|---|---|---|---|---|
| 1645460 | Cue Biopharma Inc. | CUE | Pharmaceutical Preparations (2834) | 473324577 |
Insiders
| Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
|---|---|---|---|---|---|---|---|
| 1739126 | Kerri-Ann Millar | C/O Cue Biopharma Inc. 21 Erie Street Cambridge MA 02139 | Chief Financial Officer | No | Yes | No | No |
Reported Non-Derivative Transactions
| Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|---|---|---|---|---|---|
| Common Stock | Acquisiton | 2021-08-23 | 6,667 | $0.00 | 12,433 | No | 4 | M | Direct | |
| Common Stock | Disposition | 2021-08-23 | 1,961 | $0.00 | 10,472 | No | 4 | F | Direct | |
| Common Stock | Acquisiton | 2021-10-01 | 1,251 | $7.50 | 11,723 | No | 4 | M | Direct | |
| Common Stock | Disposition | 2021-10-01 | 1,251 | $14.21 | 10,472 | No | 4 | S | Direct |
| Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|
| No | 4 | M | Direct | |
| No | 4 | F | Direct | |
| No | 4 | M | Direct | |
| No | 4 | S | Direct |
Reported Derivative Transactions
| Sec. Name | Sec. Type | Acquisiton - Disposition | Date | Amount | Price | Amount - 2 | Price - 2 |
|---|---|---|---|---|---|---|---|
| Common Stock | Restricted Stock Units | Disposition | 2021-08-23 | 6,667 | $0.00 | 6,667 | $0.00 |
| Common Stock | Stock Option (right to buy) | Disposition | 2021-10-01 | 1,251 | $0.00 | 1,251 | $7.50 |
| Remaning Holdings | Exercise Date | Expiration Date | Equity Swap Involved | Transaction Form Type | Transaction Code | Nature of Ownership |
|---|---|---|---|---|---|---|
| 6,667 | No | 4 | M | Direct | ||
| 53,749 | 2024-12-27 | No | 4 | M | Direct |
Footnotes
- Represents shares of common stock received upon vesting of a restricted stock unit award.
- The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on June 16, 2021.
- The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $14.01 to $14.46, inclusive. The reporting person undertakes to provide to Cue Biopharma, Inc., any security holder of Cue Biopharma, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote (3) to this Form 4.
- Each restricted stock unit award represents a contingent right to receive one share of common stock.
- Represents a restricted stock unit award granted on August 21, 2020. The restricted stock units vest in three equal annual installments beginning on August 21, 2020.
- The option vests in eight equal semi-annual installments beginning March 25, 2018.
Billionaire Hedge Funds
